Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-8

  Avogadri, Francesca ^a   Merghoub, Taha ^a   Maughan, Maureen F ^b   Hirschhorn Cymerman, Daniel ^a   Morris, John ^b   Ritter, Erika ^c   Olmsted, Robert ^b   Houghton, Alan N ^a   Wolchok, Jedd D ^a,c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b AlphaVax Inc   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN G; MELANOMA DIFFERENTIATION ANTIGEN; MELANOMA VACCINE; TYROSINASE RELATED PROTEIN 2; UNCLASSIFIED DRUG; CANCER VACCINE; DOPACHROME ISOMERASE; ISOMERASE;

ALPHA VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNOSTIMULATION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REPLICON; VACCINE PRODUCTION; VIRUS PARTICLE; ANIMAL; C57BL MOUSE; GENE EXPRESSION; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE MUTANT; PHYSIOLOGY; TUMOR CELL LINE;

ALPHAVIRUS; MUS MUSCULUS;

ALPHAVIRUS; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOTHERAPY; INTRAMOLECULAR OXIDOREDUCTASES; MELANOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REPLICON;

EID: 77958592614     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012670     Document Type: Article

References (50)

1. Hearing VJ, Tsukamoto K, Urabe K, Kameyama K, Montague PM, et al. (1992) Functional properties of cloned melanogenic proteins. Pigment Cell Res 5: 264-270.
2. Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, et al. (2000) Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med 191: 1221-1232.
3. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3: 991-998.
4. Khong HT, Restifo NP (2002) Natural selection of tumor variants in the generation of ''tumor escape'' phenotypes. Nat Immunol 3: 999-1005.
5. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, et al. (2009) Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
6. Brandmaier AG, Leitner WW, Ha SP, Sidney J, Restifo NP, et al. (2009) High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. J Immunother 32: 677-688.
7. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NY- ESO-1. N Engl J Med 358: 2698-2703.
8. Weiner LM, Dhodapkar MV, Ferrone S (2009) Monoclonal antibodies for cancer immunotherapy. Lancet 373: 1033-1040.
9. Uchi H, Stan R, Turk MJ, Engelhorn ME, Rizzuto GA, et al. (2006) Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. Adv Immunol 90: 215-241.
10. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ (1982) Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 156: 1755-1766.
11. Brichard V, Van Pel A, Wolfel T, Wolfel C, De Plaen E, et al. (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178: 489-495.
12. Yuan J, Page DB, Ku GY, Li Y, Mu Z, et al. (2010) Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapy. Cancer Immun 10: 1.
13. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein. J Exp Med 182: 1609-1614.
14. Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, et al. (2008) Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. Cancer Res 68: 9884-9891.
15. Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, et al. (1998) Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102: 1258-1264.
16. Steitz J, Bruck J, Steinbrink K, Enk A, Knop J, et al. (2000) Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 86: 89-94.
17. Riezebos-Brilman A, de Mare A, Bungener L, Huckriede A, Wilschut J, et al. (2006) Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy. J Clin Virol 35: 233-243.
18. Lyons JA, Sheahan BJ, Galbraith SE, Mehra R, Atkins GJ, et al. (2007) Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther 14: 503-513.
19. Colmenero P, Liljestrom P, Jondal M (1999) Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther 6: 1728-1733.
20. Nelson EL, Prieto D, Alexander TG, Pushko P, Lofts LA, et al. (2003) Venezuelan equine encephalitis replicon immunization overcomes intrinsic tolerance and elicits effective anti-tumor immunity to the 'self' tumor-associated antigen, neu in a rat mammary tumor model. Breast Cancer Res Treat 82: 169-183.
21. Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, et al. (2003) Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med 9: 33-39.
22. Chen M, Barnfield C, Naslund TI, Fleeton MN, Liljestrom P (2005) MyD88 expression is required for efficient cross-presentation of viral antigens from infected cells. J Virol 79: 2964-2972.
23. Ni B, Gao W, Zhu B, Lin Z, Jia Z, et al. (2005) Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model. Cancer Immunol Immunother 54: 489-498.
24. Bernstein DI, Reap EA, Katen K, Watson A, Smith K, et al. (2009) Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 28: 484-493.
25. Berglund P, Fleeton MN, Smerdou C, Liljestrom P (1999) Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice. Vaccine 17: 497-507.
26. Zhou X, Berglund P, Zhao H, Liljestrom P, Jondal M (1995) Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc Natl Acad Sci U S A 92: 3009-3013.
27. Fleeton MN, Liljestrom P, Sheahan BJ, Atkins GJ (2000) Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 81: 749-758.
28. Sundback M, Douagi I, Dayaraj C, Forsell MN, Nordstrom EK, et al. (2005) Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles. Virology 341: 190-202.
29. Durso RJ, Andjelic S, Gardner JP, Margitich DJ, Donovan GP, et al. (2007) A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 13: 3999-4008.
30. Diebold SS, Schulz O, Alexopoulou L, Leitner WW, Flavell RA, et al. (2009) Role of TLR3 in the immunogenicity of replicon plasmid-based vaccines. Gene Ther 16: 359-366.
31. Pichlmair A, Schulz O, Tan CP, Rehwinkel J, Kato H, et al. (2009) Activation of MDA5 requires higher order RNA structures generated during virus infection. J Virol.
32. Leitner WW, Bergmann-Leitner ES, Hwang LN, Restifo NP (2006) Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine 24: 5110-5118.
33. Goldberg SM, Bartido SM, Gardner JP, Guevara-Patino JA, Montgomery SC, et al. (2005) Comparison of two cancer vaccines targeting tyrosinase: plasmid DNA and recombinant alphavirus replicon particles. Clin Cancer Res 11: 8114-8121.
34. Becker JC, Houben R, Schrama D, Voigt H, Ugurel S, et al. (2010) Mouse models for melanoma: a personal perspective. Exp Dermatol 19: 157-164.
35. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, el-Gamil M, et al. (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185: 453-459.
36. Engelhorn ME, Guevara-Patino JA, Noffz G, Hooper AT, Lou O, et al. (2006) Autoimmunity and tumor immunity induced by immune responses to mutations in self. Nat Med 12: 198-206.
37. Steel KP, Davidson DR, Jackson IJ (1992) TRP-2/DT, a new early melanoblast marker, shows that steel growth factor (c-kit ligand) is a survival factor. Development 115: 1111-1119.
38. Yamaguchi Y, Brenner M, Hearing VJ (2007) The regulation of skin pigmentation. J Biol Chem 282: 27557-27561.
39. Olivares C, Solano F (2009) New insights into the active site structure and catalytic mechanism of tyrosinase and its related proteins. Pigment Cell Melanoma Res 22: 750-760.
40. Negroiu G, Dwek RA, Petrescu SM (2003) The inhibition of early N-glycan processing targets TRP-2 to degradation in B16 melanoma cells. J Biol Chem 278: 27035-27042.
41. Costin GE, Valencia JC, Wakamatsu K, Ito S, Solano F, et al. (2005) Mutations in dopachrome tautomerase (Dct) affect eumelanin/pheomelanin synthesis, but do not affect intracellular trafficking of the mutant protein. Biochem J 391: 249-259.
42. Pawelek JM, Murray M (1986) Increase in melanin formation and promotion of cytotoxicity in cultured melanoma cells caused by phosphorylated isomers of L- dopa. Cancer Res 46: 493-497.
43. Kroumpouzos G, Urabe K, Kobayashi T, Sakai C, Hearing VJ (1994) Functional analysis of the slaty gene product (TRP2) as dopachrome tautomerase and the effect of a point mutation on its catalytic function. Biochem Biophys Res Commun 202: 1060-1068.
44. Wang RF, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med 184: 2207-2216.
45. Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6: 443-446.
46. van Spriel AB, van Ojik HH, Bakker A, Jansen MJ, van de Winkel JG (2003) Mac-1 (CD11b/CD18) is crucial for effective Fc receptor-mediated immunity to melanoma. Blood 101: 253-258.
47. Otten MA, van der Bij GJ, Verbeek SJ, Nimmerjahn F, Ravetch JV, et al. (2008) Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV. J Immunol 181: 6829-6836.
48. Bronte V, Apolloni E, Ronca R, Zamboni P, Overwijk WW, et al. (2000) Genetic vaccination with ''self'' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 60: 253-258.
49. Huang SK, Okamoto T, Morton DL, Hoon DS (1998) Antibody responses to melanoma/melanocyte autoantigens in melanoma patients. J Invest Dermatol 111: 662-667.
50. Reap EA, Morris J, Dryga SA, Maughan M, Talarico T, et al. (2007) Development and preclinical evaluation of an alphavirus replicon particle vaccine for cytomegalovirus. Vaccine 25: 7441-7449.